Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis
NCT ID: NCT02362074
Last Updated: 2021-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
401 participants
OBSERVATIONAL
2015-01-21
2020-03-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
REstore Working Ability in RheumatoiD Arthritis
NCT01405326
Health Outcomes in Rheumatoid Arthritis
NCT00346411
Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice
NCT01756235
Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers
NCT01029613
Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis
NCT03625089
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adalimumab subjects
Subjects starting Adalimumab treatment at time of enrollment.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Adult male or female ≥ 18 years old that has been newly prescribed adalimumab therapy according to the local product label and are with PROGRESS
3. Subjects should be evaluated for tuberculosis (TB) exposure/risk factors for active and latent TB
4. Subject is able to give written patient authorization and is willing to comply with the requirements of this study protocol.
Exclusion Criteria
2. Subject with a known hypersensitivity to Adalimumab, or any of its components
3. Presence of any condition that, in the opinion of the treating physician, prohibits the subject from participating in the study or obscures the assessment of the treatment of RA
4. Subjects currently participating in an investigational clinical trial
5. Subjects treated with \>1 prior biologic disease-modifying antirheumatic drugs (DMARDs) for RA. Any prior treatment with adalimumab is prohibited
6. Subjects previously treated with targeted synthetic disease modifying agent.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AbbVie Inc.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pont, Cranbrook, BC, CA /ID# 134511
Cranbrook, British Columbia, Canada
Drs. M & W Teo Inc. /ID# 148641
Penticton, British Columbia, Canada
The Arthritis Research Center /ID# 147466
Vancouver, British Columbia, Canada
Kur, Vancouver, CA /ID# 135371
Vancouver, British Columbia, Canada
Manitoba Clinic /ID# 134830
Winnipeg, Manitoba, Canada
Nexus Clinical Research /ID# 135411
St. John's, Newfoundland and Labrador, Canada
St. Clare's Mercy Hospital /ID# 136737
St. John's, Newfoundland and Labrador, Canada
Dr. Juris Lazovskis Inc. /ID# 134510
Sydney, Nova Scotia, Canada
Waterside Clinique /ID# 134190
Barrie, Ontario, Canada
Drs Nalin and Vandana Ahluwali /ID# 136485
Brampton, Ontario, Canada
Dr. Sanjay Dixit Medicine Professional Corporation /ID# 136486
Burlington, Ontario, Canada
Dr. Chrisotomor Kouroukis & Dr /ID# 151189
Dundas, Ontario, Canada
Adachi Medicine Prof. Corp /ID# 152538
Hamilton, Ontario, Canada
West Mountain Medical Center /ID# 134832
Hamilton, Ontario, Canada
Dr. Martin M.S. Lee Med Prof C /ID# 138333
Mississauga, Ontario, Canada
Brandusa Florica Med Prof Corp /ID# 134829
Mississauga, Ontario, Canada
Montgomery, Mississauga, CA /ID# 136943
Mississauga, Ontario, Canada
Credit Valley Rheumatology /ID# 134834
Mississauga, Ontario, Canada
Rajwinder S. Dhillon Medicine /ID# 147756
Niagara Falls, Ontario, Canada
Capital North Therapeutics Res /ID# 134835
Ottawa, Ontario, Canada
Setty, Owen Sound, CA /ID# 134189
Owen Sound, Ontario, Canada
The Medical Centre /ID# 134833
Peterborough, Ontario, Canada
Involved Medicine /ID# 163880
Toronto, Ontario, Canada
Dr. Samuel K Silverberg /ID# 136496
Toronto, Ontario, Canada
Institut de Rhum. de Montreal /ID# 135289
Montreal, Quebec, Canada
Jewish General Hospital /ID# 204168
Montreal, Quebec, Canada
PSS Medical Inc. /ID# 134193
Montreal, Quebec, Canada
Clinique de Rhumatologie de Montréal /ID# 162186
Montreal, Quebec, Canada
Ctr. de Rheum de l'est du QC /ID# 135410
Rimouski, Quebec, Canada
Rheum Disease Ctr of Montreal /ID# 135372
Westmount, Quebec, Canada
Dr. Latha Naik /ID# 135813
Saskatoon, Saskatchewan, Canada
Chuq - Chul /Id# 137054
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
clinical study report synopsis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P14-455
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.